Payment overview · 2025
General Payments
$886.77
47 reported records · 18 companies
Healthcare provider profile · identity verified
William Randall Turner, MD
Allopathic & Osteopathic Physicians|Family Medicine · CULLMAN, AL · NPI 1598291254
Verified facts
What the public records show
CMS Open Payments records show William Randall Turner, MD received $886.77 in general payments during 2025 across 47 reported records.
Novo Nordisk Inc accounted for 20.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 266 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Lantus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $185.05 | 20.9% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $161.26 | 18.2% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $114.64 | 12.9% | 6 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $50.43 | 5.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $49.42 | 5.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $48.11 | 5.4% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $42.32 | 4.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.73 | 4.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.91 | 3.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.05 | 2.7% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $23.70 | 2.7% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $21.09 | 2.4% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$19.71 | 2.2% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $19.19 | 2.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.25 | 1.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.73 | 1.7% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $14.25 | 1.6% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $13.93 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $886.77 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $143.64 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $122.47 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $122.47 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $82.06 | 4 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $74.13 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $57.04 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $51.47 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $48.11 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $42.48 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $42.32 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $38.79 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $36.73 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $31.91 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $24.05 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $19.19 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| Ambulatory Monitoring & Diagnostics Undivided Normalized: ambulatory monitoring diagnostics undivided |
Device | Philips North America LLC | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $12.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 180 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 266 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 152 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
74 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
180 | 47 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
266 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
89 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
152 | 39 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
152 | 37 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 568 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 460 | 136 |
| Gabapentin | Gabapentin | 446 | 118 |
| Atorvastatin Calcium | Atorvastatin Calcium | 391 | 133 |
| Amlodipine Besylate | Amlodipine Besylate | 388 | 128 |
| Losartan Potassium | Losartan Potassium | 365 | 118 |
| Pantoprazole Sodium | Pantoprazole Sodium | 363 | 124 |
| Omeprazole | Omeprazole | 351 | 109 |
| Lisinopril | Lisinopril | 330 | 103 |
| Metoprolol Succinate | Metoprolol Succinate | 272 | 83 |
| Mounjaro | Tirzepatide | 266 | 40 |
| Furosemide | Furosemide | 256 | 92 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 250 | 82 |
| Metformin Hcl | Metformin Hcl | 246 | 69 |
| Alprazolam | Alprazolam | 245 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 233 | 75 |
| Trazodone Hcl | Trazodone Hcl | 226 | 80 |
| Metformin Hcl Er | Metformin Hcl | 223 | 73 |
| Famotidine | Famotidine | 210 | 75 |
| Montelukast Sodium | Montelukast Sodium | 210 | 74 |
| Hydrochlorothiazide | Hydrochlorothiazide | 207 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 196 | 71 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 189 | 34 |
| Simvastatin | Simvastatin | 187 | 56 |
| Jardiance | Empagliflozin | 180 | 47 |
| Diclofenac Sodium | Diclofenac Sodium | 171 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 163 | 62 |
| Potassium Chloride | Potassium Chloride | 158 | 56 |
| Ezetimibe | Ezetimibe | 153 | 54 |
| Eliquis | Apixaban | 152 | 37 |
| Ozempic | Semaglutide | 152 | 39 |
| Sertraline Hcl | Sertraline Hcl | 145 | 50 |
| Tramadol Hcl | Tramadol Hcl | 138 | 35 |
| Amitriptyline Hcl | Amitriptyline Hcl | 133 | 43 |
| Methocarbamol | Methocarbamol | 133 | 48 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 131 | 107 |
| Zolpidem Tartrate | Zolpidem Tartrate | 131 | 32 |
| Meloxicam | Meloxicam | 127 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 126 | 39 |
| Donepezil Hcl | Donepezil Hcl | 123 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 121 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 119 | 40 |
| Glimepiride | Glimepiride | 116 | 33 |
| Buspirone Hcl | Buspirone Hcl | 112 | 35 |
| Lorazepam | Lorazepam | 111 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 105 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 37 |
| Clonazepam | Clonazepam | 99 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 97 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 91 | 34 |
| Januvia | Sitagliptin Phosphate | 90 | 21 |
| Trulicity | Dulaglutide | 89 | 18 |
| Mirtazapine | Mirtazapine | 86 | 29 |
| Atenolol | Atenolol | 85 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 85 | 24 |
| Allopurinol | Allopurinol | 84 | 28 |
| Carvedilol | Carvedilol | 81 | 28 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 79 | 29 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 77 | 66 |
| Farxiga | Dapagliflozin Propanediol | 74 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 70 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 69 | 18 |
| Glipizide | Glipizide | 69 | 23 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 69 | 16 |
| Fluconazole | Fluconazole | 62 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 19 |
| Fenofibrate | Fenofibrate | 61 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 61 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 61 | 19 |
| Pregabalin | Pregabalin | 59 | 22 |
| Alendronate Sodium | Alendronate Sodium | 58 | 22 |
| Azelastine Hcl | Azelastine Hcl | 57 | 34 |
| Testosterone Cypionate | Testosterone Cypionate | 57 | 13 |
| Sucralfate | Sucralfate | 56 | 30 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 53 | 47 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 53 | 15 |
| Repatha Sureclick | Evolocumab | 53 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | 17 |
| Xarelto | Rivaroxaban | 52 | suppressed |
| Finasteride | Finasteride | 49 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 14 |
| Memantine Hcl | Memantine Hcl | 49 | 15 |
| Mupirocin | Mupirocin | 49 | 33 |
| Oxycodone Hcl | Oxycodone Hcl | 48 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 16 |
| Prednisone | Prednisone | 46 | 22 |
| Bupropion Xl | Bupropion Hcl | 45 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | 16 |
| Topiramate | Topiramate | 44 | 15 |
| Azithromycin | Azithromycin | 43 | 31 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 43 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 11 |
| Celecoxib | Celecoxib | 41 | 13 |
| Fluocinonide | Fluocinonide | 41 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 25 |
| Irbesartan | Irbesartan | 40 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | 11 |
| Cephalexin | Cephalexin | 39 | 34 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 38 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 22 |
| Spiriva Respimat | Tiotropium Bromide | 36 | suppressed |
| Spironolactone | Spironolactone | 36 | 15 |
| Valsartan | Valsartan | 36 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 35 | suppressed |
| Aripiprazole | Aripiprazole | 34 | 11 |
| Diazepam | Diazepam | 34 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 21 |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 31 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 31 | 12 |
| Temazepam | Temazepam | 31 | suppressed |
| Ibuprofen | Ibuprofen | 30 | 14 |
| Icosapent Ethyl | Icosapent Ethyl | 30 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 18 |
| Tresiba Flextouch U-100 | Insulin Degludec | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 26 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 13 |
| Naproxen | Naproxen | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 14 |
| Nystatin | Nystatin | 24 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 21 |
| Raloxifene Hcl | Raloxifene Hcl | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | 13 |
| Linzess | Linaclotide | 22 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 22 | suppressed |
| Carisoprodol | Carisoprodol | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 17 |
| Nateglinide | Nateglinide | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | 11 |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Modafinil | Modafinil | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Erythromycin | Erythromycin Base | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 12 |
| Naltrexone Hcl | Naltrexone Hcl | 14 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Novolin R | Insulin Regular, Human | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $886.77 · 47 records | Novo Nordisk Inc | Ambulatory Monitoring & Diagnostics Undivided, BREZTRI, CAPLYTA, JARDIANCE, KRYSTEXXA, Kerendia, LEQEMBI, MINIMED 780G, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PAXLOVID, QULIPTA, REPATHA, REXULTI, Rybelsus, TZIELD, The Cologuard Plus Collection Kit, WAKIX, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error